|
LRIG2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62458935193399E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.33066907387547E-16 |
| Normal-vs-Stage2 |
5.31680033333259E-10 |
| Normal-vs-Stage3 |
3.33066907387547E-15 |
| Normal-vs-Stage4 |
1.76303416310475E-12 |
| Stage1-vs-Stage2 |
6.254800E-01 |
| Stage1-vs-Stage3 |
1.599000E-01 |
| Stage1-vs-Stage4 |
9.028400E-02 |
| Stage2-vs-Stage3 |
6.174000E-01 |
| Stage2-vs-Stage4 |
3.351000E-01 |
| Stage3-vs-Stage4 |
5.683000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.72082999999601E-05 |
| Normal-vs-Asian |
1.05479958101284E-10 |
| Caucasian-vs-AfricanAmerican |
3.194800E-01 |
| Caucasian-vs-Asian |
9.719400E-01 |
| AfricanAmerican-vs-Asian |
3.531800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
1.62470037423645E-12 |
| Male-vs-Female |
3.486800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.63868918434673E-12 |
| Normal-vs-Age(41-60Yrs) |
5.55111512312578E-16 |
| Normal-vs-Age(61-80Yrs) |
1.63336011382853E-12 |
| Normal-vs-Age(81-100Yrs) |
2.2878000000004E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.523400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.483200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.312000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.349600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.975600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.381400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.080400E-03 |
| Classical-VS-Follicular |
1.832370E-01 |
| Classical-VS-Other |
6.324800E-01 |
| Classical-VS-Normal |
1.62492241884138E-12 |
| Tall-VS-Follicular |
1.244010E-01 |
| Tall-VS-Other |
3.792800E-01 |
| Tall-VS-Normal |
1.66755498298699E-13 |
| Follicular-VS-Other |
9.837200E-01 |
| Follicular-VS-Normal |
4.22983870151938E-12 |
| Other-VS-Normal |
9.590300E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
8.88178419700125E-16 |
| Normal-vs-N1 |
9.64450741491873E-13 |
| N0-vs-N1 |
2.964400E-01 |
|
|
